Gemma M Austin

Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia

R. Clark, L. Bonnett, J. Apperley, 2021, Cancers.

Dual Glutathione‐S‐Transferase‐θ1 and ‐μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia

M. Pirmohamed, R. Clark, T. Holyoake, 2014, Clinical pharmacology and therapeutics.

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.

Martin C. Müller, M. Pirmohamed, S. Pushpakom, 2013, Blood.

Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) modifies energy metabolism via 5' AMP-activated protein kinase signalling in malignant cells.

R. Clark, R. Jenkins, Karen Dunn, 2019, The Biochemical journal.

Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter hOCT1 in chronic myeloid leukaemia cells

Lihui Wang, A. Holcroft, G. Austin, 2015, European journal of haematology.